Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Cancer Res
    July 2022
  1. CHENG L, Zhou S, Zhou S, Shi K, et al
    Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
    Cancer Res. 2022 Jul 20. pii: 707082. doi: 10.1158/0008-5472.CAN-22-0222.
    >> Share

    April 2022
  2. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    >> Share

    March 2022
  3. ZHANG S, Yan C, Millar DG, Yang Q, et al
    Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Cancer Res. 2022;82:773-784.
    >> Share

    February 2022
  4. GHILARDI C, Moreira Barbosa C, Brunelli L, Ostano P, et al
    PGC1alpha/beta EXPRESSION PREDICTS THERAPEUTIC RESPONSE TO OXIDATIVE PHOSPHORYLATION INHIBITION IN OVARIAN CANCER.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1223.
    >> Share

    November 2021
  5. KANAKKANTHARA A, Hou X, Ekstrom TL, Zanfagnin V, et al
    Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-0732.
    >> Share

  6. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    >> Share

    October 2021
  7. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    >> Share

    September 2021
  8. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    >> Share

  9. ZUNDELL JA, Fukumoto T, Lin J, Fatkhudinov N, et al
    Targeting the IRE1alpha/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers.
    Cancer Res. 2021 Sep 21. pii: 0008-5472.CAN-21-1545.
    >> Share

    August 2021
  10. MCDONALD JI, Diab N, Arthofer E, Hadley M, et al
    Epigenetic therapies in ovarian cancer alter repetitive element expression in a TP53-dependent manner.
    Cancer Res. 2021 Aug 25. pii: 0008-5472.CAN-20-4243.
    >> Share

  11. GEETHADEVI A, Nair A, Parashar D, Ku Z, et al
    Oncostatin M Receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth.
    Cancer Res. 2021 Aug 11. pii: 0008-5472.CAN-21-0483.
    >> Share

    July 2021
  12. NESIC K, Kondrashova O, Hurley RM, McGehee CD, et al
    Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    Cancer Res. 2021 Jul 28. pii: 0008-5472.CAN-21-0774.
    >> Share

  13. TENG K, Ford MJ, Harwalkar K, Li Y, et al
    Modeling High-grade serous ovarian carcinoma using a combination of in vivo fallopian tube electroporation and CRISPR-Cas9-mediated genome editing.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-20-1518.
    >> Share

    June 2021
  14. PATEL M, Wang Y, Bartom ET, Dhir R, et al
    The ratio of toxic-to-nontoxic microRNAs predicts platinum sensitivity in ovarian cancer.
    Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-21-0953.
    >> Share

  15. CHEN L, Zhai Y, Wang Y, Fearon ER, et al
    Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Cancer Res. 2021;81:3309-3318.
    >> Share

    May 2021
  16. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    >> Share

    April 2021
  17. SCHOUTROP E, El-Serafi I, Poiret T, Zhao Y, et al
    Mesothelin-specific CAR T cells target ovarian cancer.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-2701.
    >> Share

    February 2021
  18. BELUR NAGARAJ A, Knarr M, Sekhar S, Connor RS, et al
    The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2041.
    >> Share

    January 2021
  19. SHRESTHA R, Llaurado Fernandez M, Dawson A, Hoenisch J, et al
    Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability.
    Cancer Res. 2021 Jan 13. pii: 0008-5472.CAN-20-2222.
    >> Share

    December 2020
  20. KARLSSON T, Johansson T, Hoglund J, Ek WE, et al
    Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers.
    Cancer Res. 2020 Dec 17. pii: 0008-5472.CAN-20-2476.
    >> Share

    November 2020
  21. DRERUP JM, Deng Y, Pandeswara SL, Padron AS, et al
    CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Cancer Res. 2020;80:5063-5075.
    >> Share

  22. WANG Y, Zhao G, Condello S, Huang H, et al
    Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1488.
    >> Share

  23. WAN C, Keany MP, Dong H, Al-Alem LF, et al
    Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-1674.
    >> Share

    October 2020
  24. PARASHAR D, Nair B, Geethadevi A, George J, et al
    Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Cancer Res. 2020 Oct 21. pii: 0008-5472.CAN-19-3717.
    >> Share

  25. SHEN YA, Hong J, Asaka R, Asaka S, et al
    Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Cancer Res. 2020;80:4514-4526.
    >> Share

    September 2020
  26. TAMURA N, Shaikh N, Muliaditan D, Soliman TN, et al
    Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-0852.
    >> Share

  27. HUANG TT, Brill E, Nair JR, Zhang X, et al
    Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1439.
    >> Share

  28. AZAR WJ, Christie EL, Mitchell C, Liu DS, et al
    Non-canonical IL-6 signaling-mediated activation of YAP regulates cell migration and invasion in ovarian clear cell cancer.
    Cancer Res. 2020 Sep 11. pii: 0008-5472.CAN-19-3044.
    >> Share

  29. CARLES A, Trigo-Gonzalez G, Cao Q, Cheng SG, et al
    The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
    Cancer Res. 2020;80:3480-3491.
    >> Share

  30. WEIS-BANKE SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, et al
    Mutant FOXL2(C134W) Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.
    Cancer Res. 2020;80:3466-3479.
    >> Share

  31. TUBEUF H, Caputo SM, Sullivan T, Rondeaux J, et al
    Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.
    Cancer Res. 2020;80:3593-3605.
    >> Share

    August 2020
  32. ZONG X, Wang W, Ozes A, Fang F, et al
    EZH2-mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-0458.
    >> Share

  33. PALMER AC, Plana D, Gao H, Korn JM, et al
    A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-19-3850.
    >> Share

  34. GEISTLINGER L, Oh S, Ramos M, Schiffer L, et al
    Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-20-0521.
    >> Share

    July 2020
  35. ASARE-WEREHENE M, Communal L, Carmona E, Han Y, et al
    Plasma gelsolin inhibits CD8+ T cell function and regulates glutathione production to confer chemoresistance in ovarian cancer.
    Cancer Res. 2020 Jul 8. pii: 0008-5472.CAN-20-0788.
    >> Share

    June 2020
  36. HUANG H, Wang Y, Kandpal M, Zhao G, et al
    FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-19-4044.
    >> Share

    May 2020
  37. MATEI D, Nephew KP
    Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
    Cancer Res. 2020 May 7. pii: 0008-5472.CAN-19-3837.
    >> Share

    April 2020
  38. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    >> Share

    February 2020
  39. MCCOOL KW, Freeman ZT, Zhai Y, Wu R, et al
    Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    Cancer Res. 2020;80:877-889.
    >> Share

  40. MUKHERJEE A, Chiang CY, Daifotis HA, Nieman KM, et al
    Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance.
    Cancer Res. 2020 Feb 13. pii: 0008-5472.CAN-19-1999.
    >> Share

    January 2020
  41. ZELEZNIK OA, Eliassen AH, Kraft P, Poole EM, et al
    A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2567.
    >> Share

  42. TRABERT B, Tworoger SS, O'Brien KM, Townsend MK, et al
    The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3).
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-2850.
    >> Share

  43. ASEM M, Young AM, Oyama C, Claure De La Zerda AG, et al
    Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-1601.
    >> Share

    December 2019
  44. NACARELLI T, Fukumoto T, Zundell JA, Fatkhutdinov N, et al
    NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer.
    Cancer Res. 2019 Dec 19. pii: 0008-5472.CAN-19-2830.
    >> Share

  45. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
    Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
    Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
    >> Share

    November 2019
  46. LI C, Course MM, McNeish IA, Drescher CW, et al
    Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models.
    Cancer Res. 2019 Nov 14. pii: 0008-5472.CAN-19-1044.
    >> Share

    October 2019
  47. KANAKKANTHARA A, Kurmi K, Ekstrom TL, Hou X, et al
    BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    Cancer Res. 2019 Oct 16. pii: 0008-5472.CAN-19-1405.
    >> Share

  48. CARBONE M, Melino G
    Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives.
    Cancer Res. 2019;79:5149-5150.
    >> Share

    September 2019
  49. CHUI MH, Doodnauth SA, Erdmann N, Tiedemann RE, et al
    Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-18-3029.
    >> Share

    June 2019
  50. FUKUMOTO T, Zhu H, Nacarelli T, Karakashev S, et al
    N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.
    Cancer Res. 2019;79:2812-2820.
    >> Share

    April 2019
  51. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    >> Share

    March 2019
  52. PRICE C, Gill S, Ho ZV, Davidson SM, et al
    Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers.
    Cancer Res. 2019 Mar 21. pii: 0008-5472.CAN-18-2674.
    >> Share

    February 2019
  53. MCCORMICK PN, Greenwood HE, Glaser M, Maddocks ODK, et al
    Assessment of Tumor Redox Status through (S)-4-(3-[(18)F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc (-) Activity.
    Cancer Res. 2019;79:853-863.
    >> Share

    January 2019
  54. DYER A, Schoeps B, Frost S, Jakeman P, et al
    Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
    Cancer Res. 2019;79:331-345.
    >> Share

  55. SHEN J, Zhao W, Ju Z, Wang L, et al
    PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Cancer Res. 2019;79:311-319.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016